Eli Lilly Weight-Loss Drug Trial Showed Mixed Results
A new dual-action medication led to significant weight loss in a study, but also saw higher rates of treatment discontinuation.
Updated on Sept. 30, 2026 in Weight Loss
Live Poll
Do you trust that new weight-loss drugs adequately weigh health benefits against potential side effects?
Eli Lilly reported results from a Phase 2 trial of EloraTZP, an experimental weight-loss drug combining tirzepatide with the amylin receptor agonist eloralintide. The medication showed promising weight-loss potential in adults with obesity and diabetes over a one-year period.
Why it matters
By combining therapies that target multiple hormonal pathways, this drug seeks to improve outcomes for patients managing both weight and Type 2 diabetes. The findings provide a preliminary look at how newer combinations compare to current standard-of-care treatments.
In a Phase 2 trial of 367 adults with obesity and diabetes, participants taking the experimental drug EloraTZP lost between 13.2% and 23.3% of their body weight over one year. These preliminary results showed higher rates of gastrointestinal side effects and discontinuation compared to Zepbound.
The players
Eli Lilly
An Indianapolis-based pharmaceutical company that develops metabolic and diabetes therapies including Zepbound and tirzepatide.
The details
EloraTZP functions by combining tirzepatide with an experimental amylin receptor agonist called eloralintide. While tirzepatide works on GLP-1 and GIP receptors to regulate blood sugar and appetite, the addition of an amylin receptor agonist aims to further signal fullness through a distinct hormonal pathway. This dual approach is designed to enhance weight loss beyond current single-pathway medications, though the study noted higher discontinuation rates of 27% for the combination therapy.
Timeline
September 30, 2026: Eli Lilly released Phase 2 trial results for EloraTZP.
2030: Projected annual sales for eloralintide reach $2.6 billion.
Health Landscape
This research follows a trend of combining hormonal therapies to improve outcomes beyond the current GLP-1 standard of care. The data presented at the European Association for the Study of Diabetes conference suggests a move toward more potent, multi-pathway treatments for metabolic health.
Patients currently managing weight or diabetes should note that this drug is still in clinical testing and not yet available for clinical use. Any shifts in your treatment plan should always be a conversation held with your physician to ensure you are using proven, FDA-approved options.
The takeaway
While experimental combinations may offer increased potency, they can come with higher rates of gastrointestinal side effects and treatment challenges. Keep following established, FDA-approved medications and discuss any interest in clinical trials with your doctor.
Further reading
For more on evolving research in this area, visit Weight Loss.
Live Poll
Do you trust that new weight-loss drugs adequately weigh health benefits against potential side effects?
